Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADVM NASDAQ:BDTX NASDAQ:PASG NASDAQ:TCRR NASDAQ:TSHA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADVMAdverum Biotechnologies$3.07+1.7%$2.81$1.78▼$8.56$63.37M0.9277,460 shs34,937 shsBDTXBlack Diamond Therapeutics$3.19-1.8%$2.86$1.20▼$6.23$185.04M2.93775,043 shs906,508 shsPASGPassage Bio$6.95-0.7%$6.72$5.12▼$26.60$22.25M1.8232,439 shs41,417 shsTCRRTCR2 Therapeutics$1.48$1.65$0.82▼$3.88$58.11M1.95494,777 shsN/ATSHATaysha Gene Therapies$3.02-1.6%$2.83$1.05▼$3.40$837.48M0.983.38 million shs3.00 million shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADVMAdverum Biotechnologies+1.66%-13.28%+7.34%+32.33%-57.54%BDTXBlack Diamond Therapeutics-1.85%+4.59%+15.58%+37.50%-48.47%PASGPassage Bio-0.71%-2.37%0.00%-8.67%-56.92%TCRRTCR2 Therapeutics0.00%0.00%0.00%0.00%0.00%TSHATaysha Gene Therapies-1.63%-6.79%+2.72%+18.43%+31.88%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADVMAdverum Biotechnologies$3.07+1.7%$2.81$1.78▼$8.56$63.37M0.9277,460 shs34,937 shsBDTXBlack Diamond Therapeutics$3.19-1.8%$2.86$1.20▼$6.23$185.04M2.93775,043 shs906,508 shsPASGPassage Bio$6.95-0.7%$6.72$5.12▼$26.60$22.25M1.8232,439 shs41,417 shsTCRRTCR2 Therapeutics$1.48$1.65$0.82▼$3.88$58.11M1.95494,777 shsN/ATSHATaysha Gene Therapies$3.02-1.6%$2.83$1.05▼$3.40$837.48M0.983.38 million shs3.00 million shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADVMAdverum Biotechnologies+1.66%-13.28%+7.34%+32.33%-57.54%BDTXBlack Diamond Therapeutics-1.85%+4.59%+15.58%+37.50%-48.47%PASGPassage Bio-0.71%-2.37%0.00%-8.67%-56.92%TCRRTCR2 Therapeutics0.00%0.00%0.00%0.00%0.00%TSHATaysha Gene Therapies-1.63%-6.79%+2.72%+18.43%+31.88%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADVMAdverum Biotechnologies 2.75Moderate Buy$19.75543.32% UpsideBDTXBlack Diamond Therapeutics 3.14Buy$11.67265.73% UpsidePASGPassage Bio 3.00Buy$75.67988.73% UpsideTCRRTCR2 Therapeutics 0.00N/AN/AN/ATSHATaysha Gene Therapies 3.00Buy$8.29174.36% UpsideCurrent Analyst Ratings BreakdownLatest TSHA, TCRR, BDTX, PASG, and ADVM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/3/2025BDTXBlack Diamond TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$8.009/3/2025BDTXBlack Diamond TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$8.008/14/2025PASGPassage BioCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$260.00 ➝ $67.008/13/2025ADVMAdverum BiotechnologiesChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$33.008/13/2025PASGPassage BioWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$40.008/13/2025TSHATaysha Gene TherapiesWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$7.50 ➝ $8.008/12/2025TSHATaysha Gene TherapiesChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.00 ➝ $10.008/11/2025BDTXBlack Diamond TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/11/2025BDTXBlack Diamond TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$12.00 ➝ $10.007/11/2025TSHATaysha Gene TherapiesBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$8.007/1/2025BDTXBlack Diamond TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeOutperform$11.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADVMAdverum Biotechnologies$1M64.41N/AN/A$3.40 per share0.90BDTXBlack Diamond Therapeutics$70M2.59N/AN/A$1.47 per share2.17PASGPassage BioN/AN/AN/AN/A$19.84 per shareN/ATCRRTCR2 TherapeuticsN/AN/AN/AN/A$2.58 per shareN/ATSHATaysha Gene Therapies$8.10M101.73N/AN/A$0.35 per share8.63Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADVMAdverum Biotechnologies-$130.93M-$7.85N/AN/AN/AN/A-297.29%-101.40%11/3/2025 (Estimated)BDTXBlack Diamond Therapeutics-$69.68M$0.2313.87N/AN/AN/A12.70%9.58%11/4/2025 (Estimated)PASGPassage Bio-$64.77M-$18.16N/AN/AN/AN/A-103.87%-59.95%11/12/2025 (Estimated)TCRRTCR2 Therapeutics-$151.82M-$4.20N/AN/AN/AN/A-97.81%-69.35%N/ATSHATaysha Gene Therapies-$89.30M-$0.34N/AN/AN/A-1,144.97%-78.44%-44.82%11/12/2025 (Estimated)Latest TSHA, TCRR, BDTX, PASG, and ADVM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025ADVMAdverum Biotechnologies-$2.24-$2.34-$0.10-$2.34N/AN/A8/12/2025Q2 2025PASGPassage Bio-$4.00-$2.96+$1.04-$2.96N/AN/A8/12/2025Q2 2025TSHATaysha Gene Therapies-$0.07-$0.09-$0.02-$0.09$1.61 million$1.99 million8/7/2025Q2 2025BDTXBlack Diamond Therapeutics-$0.25-$0.19+$0.06-$0.19N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADVMAdverum BiotechnologiesN/AN/AN/AN/AN/ABDTXBlack Diamond TherapeuticsN/AN/AN/AN/AN/APASGPassage BioN/AN/AN/AN/AN/ATCRRTCR2 TherapeuticsN/AN/AN/AN/AN/ATSHATaysha Gene TherapiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADVMAdverum BiotechnologiesN/A1.541.54BDTXBlack Diamond TherapeuticsN/A8.738.73PASGPassage BioN/A3.053.05TCRRTCR2 TherapeuticsN/A2.962.96TSHATaysha Gene Therapies0.1712.4812.48Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADVMAdverum Biotechnologies48.17%BDTXBlack Diamond Therapeutics95.47%PASGPassage Bio53.48%TCRRTCR2 Therapeutics64.76%TSHATaysha Gene Therapies77.70%Insider OwnershipCompanyInsider OwnershipADVMAdverum Biotechnologies6.00%BDTXBlack Diamond Therapeutics5.97%PASGPassage Bio5.00%TCRRTCR2 Therapeutics25.01%TSHATaysha Gene Therapies3.78%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADVMAdverum Biotechnologies19020.98 million19.73 millionOptionableBDTXBlack Diamond Therapeutics9056.94 million53.54 millionOptionablePASGPassage Bio1303.18 million3.04 millionOptionableTCRRTCR2 Therapeutics13739.26 million29.44 millionNot OptionableTSHATaysha Gene Therapies180272.80 million262.48 millionOptionableTSHA, TCRR, BDTX, PASG, and ADVM HeadlinesRecent News About These CompaniesInsider Selling: Taysha Gene Therapies (NASDAQ:TSHA) Insider Sells 200,000 Shares of StockSeptember 14 at 5:32 PM | marketbeat.comTaysha Gene Therapies (NASDAQ:TSHA) Insider Sukumar Nagendran Sells 200,000 SharesSeptember 13 at 6:38 AM | insidertrades.comSiren L.L.C. Sells 87,738 Shares of Taysha Gene Therapies, Inc. $TSHASeptember 13 at 5:56 AM | marketbeat.comTaysha Gene Therapies, Inc. $TSHA Shares Acquired by Octagon Capital Advisors LPSeptember 11, 2025 | marketbeat.comTaysha Gene Therapies (NASDAQ:TSHA) Sets New 52-Week High - Here's WhySeptember 7, 2025 | americanbankingnews.comTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)September 5, 2025 | globenewswire.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $8.29 Consensus PT from AnalystsSeptember 5, 2025 | americanbankingnews.comTaysha Gene Therapies, Inc. $TSHA Stake Increased by ADAR1 Capital Management LLCSeptember 4, 2025 | marketbeat.comPalo Alto Investors LP Purchases 608,200 Shares of Taysha Gene Therapies, Inc. $TSHASeptember 4, 2025 | marketbeat.comNuveen LLC Acquires New Stake in Taysha Gene Therapies, Inc. $TSHASeptember 4, 2025 | marketbeat.comTaysha Gene Therapies, Inc.September 3, 2025 | edition.cnn.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Consensus Rating of "Buy" from BrokeragesSeptember 3, 2025 | marketbeat.comPiper Sandler Maintains a Buy on Taysha Gene Therapies (TSHA), Sets a PT of $9August 25, 2025 | msn.comKovitz Investment Group Partners LLC Invests $407,000 in Taysha Gene Therapies, Inc. $TSHAAugust 24, 2025 | marketbeat.comFY2025 Earnings Forecast for TSHA Issued By Chardan CapitalAugust 19, 2025 | marketbeat.comCantor Fitzgerald Issues Negative Forecast for TSHA EarningsAugust 17, 2025 | marketbeat.comTaysha Gene Therapies price target raised to $14 from $11 at CanaccordAugust 13, 2025 | msn.com4TSHA : A Glimpse Into The Expert Outlook On Taysha Gene Therapies Through...August 13, 2025 | benzinga.comTaysha Gene Therapies Inc (TSHA) Q2 2025 Earnings Call Highlights: Regulatory Milestones and ...August 13, 2025 | finance.yahoo.comTaysha Gene Therapies price target raised to $10 from $9 at ChardanAugust 13, 2025 | msn.comTaysha plans pivotal TSHA-102 trial enrollment in Q4 2025, extends cash runway to 2028August 13, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTSHA, TCRR, BDTX, PASG, and ADVM Company DescriptionsAdverum Biotechnologies NASDAQ:ADVM$3.07 +0.05 (+1.66%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$3.08 +0.01 (+0.16%) As of 09/15/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.Black Diamond Therapeutics NASDAQ:BDTX$3.19 -0.06 (-1.85%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$3.20 +0.00 (+0.16%) As of 07:26 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Passage Bio NASDAQ:PASG$6.95 -0.05 (-0.71%) Closing price 09/15/2025 03:53 PM EasternExtended Trading$7.14 +0.19 (+2.81%) As of 05:53 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.TCR2 Therapeutics NASDAQ:TCRRTCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle on May 29, 2015 and is headquartered in Cambridge, MA.Taysha Gene Therapies NASDAQ:TSHA$3.02 -0.05 (-1.63%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$3.04 +0.02 (+0.79%) As of 07:31 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Reddit Hits Record Highs: Why Wall Street Is Taking Notice Royal Caribbean's 33% Dividend Hike Signals Deeper Growth FuelCell Energy's Stock: Is a Fundamental Breakout Underway? After a Strong Wall Street Debut, Klarna's Real Work Begins MarketBeat Week in Review – 09/08 - 09/12 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
